Search Result

Results for "

MAT2A Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Methionine Adenosyltransferase (MAT) (37) Apoptosis (1) Fluorescent Dye (1) Isotope-Labeled Compounds (1) NF-κB (1) p38 MAPK (1) Reactive Oxygen Species (ROS) (1) Reference Standards (1) Somatostatin Receptor (3) Wnt (1)
By Research Areas:	Cancer (42) Neurological Disease (2)

Inhibitors & Agonists

Isotope-Labeled Compounds

Targets Recommended: Methionine Adenosyltransferase (MAT)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-138630

AG-270 5+ Cited Publications	Methionine Adenosyltransferase (MAT)	Cancer
AG-270 is an allosteric, noncompetitive, first-in-class, reversible and orally active *MAT2A* inhibitor, with an IC₅₀ of 14 nM .

HY-107778

PF-9366 Maximum Cited Publications 18 Publications Verification	Methionine Adenosyltransferase (MAT)	Cancer
PF-9366 is a human methionine adenosyltransferase 2A (Mat2A) inhibitor, with an IC₅₀ of 420 nM and a K_d of 170 nM.

HY-112569

MAT2A inhibitor 2	Methionine Adenosyltransferase (MAT) NF-κB p38 MAPK	Cancer
MAT2A inhibitor 2 is an inhibitor of methionine adenosine transferase 2A (MAT2A) with oral activity. MAT2A inhibitor 2 can be used in osteoporosis study

HY-136144

FIDAS-5 5+ Cited Publications	Methionine Adenosyltransferase (MAT)	Cancer
FIDAS-5 is a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC₅₀ of 2.1 μM. FIDAS-5 effectively competes against S-adenosylmethionine (SAM) for *MAT2A* binding. FIDAS-5 has anticancer activities .

HY-112130

AGI-24512 2 Publications Verification	Methionine Adenosyltransferase (MAT)	Cancer
AGI-24512 is a potent methionine adenosyltransferase 2α (MAT2A) inhibitor, with an IC₅₀ of 8 nM. AGI-24512 triggers DNA damage response. AGI-24512 can block proliferation of MTAP-deleted cancer cells in vitro. AGI-24512 can be used for researching anticancer .

HY-112131

MAT2A inhibitor 1 1 Publications Verification	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A inhibitor 1 is a methionine adenosyltransferase 2A (MATA2) inhibitor with an IC₅₀ less than l00 nM .

HY-139139

MAT2A inhibitor 3	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A inhibitor 3 is a methionine adenosyltransferase 2A (MAT2A) inhibitor extracted from patent WO2020123395A1, compound 24, has an IC₅₀ of <200 nM. MAT2A inhibitor 3 can be used for the research of cancers .

HY-162353

AZ'9567		Cancer
AZ'9567 is an orally active *MAT2a* inhibitor with a pIC₅₀ of 9.1. AZ'9567 binds to *MAT2a* allosterically, reduces the synthesis of SAM, decreases SDMA levels, and exerts antiproliferative effects on MTAP-knockout cells. AZ'9567 depletes SAM, causes methionine accumulation in plasma and tissues, triggers adaptive disorders in one-carbon metabolism, transsulfuration metabolism and lipid metabolism, and induces oxidative stress, hepatic steatosis and lipid homeostasis imbalance. AZ'9567 can be used in studies related to MTAP-deficient/deleted cancers .

HY-139536

MAT2A inhibitor 4	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A inhibitor 4 is an inhibitor of the catalytic subunit of methionine S-adenosyltransferase-2 (MAT2A). MAT2A inhibitor 4 can be used for the research of cancer .

HY-169257

SCR-7952	Methionine Adenosyltransferase (MAT)	Cancer
SCR-7952 is a *MAT2A* inhibitor, with IC₅₀ of 18.7 nM. SCR-7952 can be used in anti-cancer research .

HY-145777

AGI-43192	Methionine Adenosyltransferase (MAT)	Neurological Disease Cancer
AGI-43192 is a potent and orally active inhibitor of methionine adenosyltransferase 2A (MAT2A) that limitedly penetrates the blood-brain barrier. AGI-43192 exhibits inhibitory activitity against MAT2A and S-adenosyl methionine (SAM) in HCT-116 MTAP-null cells with IC₅₀s of 32 and 14 nM. AGI-43192 can significantly inhibit the proliferation of HCT-116 cells and tumor growth. AGI-43192 can be used to study the role of SAM regulation in the central nervous system (CNS) and colon cancer .

HY-145778

AGI-41998	Methionine Adenosyltransferase (MAT)	Neurological Disease Cancer
AGI-41998 is a potent and orally active inhibitor of methionine adenosyltransferase 2A (MAT2A) that effectively penetrates the blood-brain barrier. AGI-41998 exhibits inhibitory activities against MAT2A and S-adenosyl methionine (SAM) in HCT-116 MTAP-null cells with IC₅₀s of 22 nM and 34 nM. AGI-41998 can significantly inhibit the proliferation of HCT-116 cells and tumor growth. AGI-41998 can be used to study the role of SAM regulation in the central nervous system (CNS) and colon cancer .

HY-136145

FIDAS-3	Wnt	Cancer
FIDAS-3 is a stilbene derivative and is a potent Wnt inhibitor with an IC₅₀ of 4.9 μM for methionine S-adenosyltransferase 2A (MAT2A). FIDAS-3 effectively competes against S-adenosylmethionine (SAM) for *MAT2A* binding. FIDAS-3 has anticancer activities .

HY-163656

MAT2A inhibitor 5	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A inhibitor 5(compound 39) is an orally active, selectivity and blood-brain permeability inhibitor of *MAT2A* with the IC₅₀ of 11 nM. MAT2A inhibitor 5 inhibits tumor cell growth in vivo .

HY-159156

MAT2A inhibitor 6	Methionine Adenosyltransferase (MAT) Apoptosis Fluorescent Dye	Cancer
MAT2A inhibitor 6 (Compound 3N-h) is a specific *MAT2A* inhibitor with oral activity and yellow fluorescence (IC₅₀=26 nM), capable of visualizing MAT2A both in vitro and in vivo (λex = 430 nm, λem = 585 nm). MAT2A inhibitor 6 can induce apoptosis and has anticancer activity, which can be used in cancer research .

HY-162010

MAT2A-IN-13	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-13 is a potent and orally active methionine adenosyltransferase 2A (MAT2A) inhibitor with a favorable pharmacokinetic profile. MAT2A-IN-13 shows in vivo potency in an HCT-116 MTAP-deleted xenograft model. MAT2A-IN-13 can be used for MTAP-Deleted tumors research .

HY-168445

MAT2A-IN-21	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-21 (compound 28) is a potent methionine adenosyltransferase 2A (MAT2A) inhibitor with an IC₅₀ of 49 nM. MAT2A-IN-21 selectivity inhibits MTAP-deficient cancer cells .

HY-161298

MAT2A-IN-15	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-15 (compound 8) is an inhibitor of *MAT2A* .

HY-170500

MAT2A-IN-17	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-17 is a potent *MAT2A* inhibitor with an IC₅₀ < 100 nM. MAT2A-IN-17 can be used in the study of cancer .

HY-162135

MAT2A-IN-14	Methionine Adenosyltransferase (MAT) Reactive Oxygen Species (ROS)	Cancer
MAT2A-IN-14 (compound H3) is a *MAT2A* inhibitor, and generates reactive oxygen species after sonication to specifically degrade cellular MAT2A via rapid oxidative reactions. Combination of MAT2A-IN-14 and sonication induces 87% MAT2A depletion in human colon cancer cell .

HY-170503

MAT2A-IN-20	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-20 (Compound A49) is an inhibitor for methionine adenosyltransferase 2A (MAT2A) with an IC₅₀ ≤50 nM. MAT2A-IN-20 inhibits human UGT1A1 with an IC₅₀ of 28.45 μM. MAT2A-IN-20 exhibits antitumor in mouse models .

HY-149915

MAT2A-IN-10	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-10 (Compound 28) is an orally active *MAT2A* inhibitor with an IC₅₀ of 26 nM. MAT2A-IN-10 can be used for the research of cancer .

HY-155149

MAT2A-IN-12	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A Allosteric inhibitor 2 is a potent and selective *MAT2A* allosteric inhibitor with an IC₅₀ of 5 nM. MAT2A Allosteric inhibitor 2 shows nanomolar activity (IC₅₀=5 μM) in the the proliferation assay (MTAP ^-/- cell line) .

HY-155148

MAT2A-IN-11	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A Allosteric inhibitor 1 (compound 5) is a MAT2A selective inhibitor of methionine adenosyltransferase (MAT) with an IC₅₀ of 6.8 nM .

HY-170421

MAT2A-IN-16	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-16 is a *MAT2A* inhibitor and inhibits cell proliferation of MTAP ^-/- HCT-116 cells (IC₅₀: 20 nM) .

HY-144184

MAT2A-IN-6	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-6 is a potent inhibitor of *MAT2A. The expression level of MAT2A* is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-6 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-6 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 18) .

HY-144185

MAT2A-IN-7	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-7 is a potent inhibitor of *MAT2A. The expression level of MAT2A* is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-7 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-7 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 24) .

HY-144181

MAT2A-IN-5	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-5 is a potent inhibitor of *MAT2A. The expression level of MAT2A* is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-5 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-5 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 1) .

HY-142929

MAT2A-IN-2	Somatostatin Receptor	Cancer
MAT2A-IN-2 is a potent inhibitor of *MAT2A. The expression level of MAT2A* is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-2 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-2 has the potential for the research of cancer diseases (extracted from patent WO2020243376A1, compound 172) .

HY-142928

MAT2A-IN-1	Somatostatin Receptor	Cancer
MAT2A-IN-1 is a potent inhibitor of *MAT2A. The expression level of MAT2A* is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-1 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-1 has the potential for the research of cancer diseases (extracted from patent WO2021139775A1, compound 64) .

HY-142930

MAT2A-IN-3	Somatostatin Receptor	Cancer
MAT2A-IN-3 is a potent inhibitor of *MAT2A. The expression level of MAT2A* is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-3 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-3 has the potential for the research of cancer diseases (extracted from patent WO2019191470A1, compound 265) .

HY-144179

MAT2A-IN-4	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-4 is a methionine adenosyltransferase 2A (MAT2A) inhibitor extracted from patent WO2020123395A1 compound 426 . MAT2A-IN-4 can be used for the research of cancer .

HY-170905S

MAT2A-IN-22	Methionine Adenosyltransferase (MAT) Isotope-Labeled Compounds	Cancer
MAT2A-IN-22 (Compound 29-1) is a BBB-penetrable and orally active *MAT2A* inhibitor with an IC₅₀ of 4 nM. MAT2A-IN-22 shows selectivity and inhibitory activity against MTAP-deficient cancer cell lines. MAT2A-IN-22 has anti-tumor effects .

HY-173281

MAT2A-IN-24	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-24 (Compound 9) is an inhibitor of methionine adenosyltransferase 2a (MAT2a). The IC₅₀ value for the inhibition of *MAT2a* is 20 nM, and the IC₅₀ value for the antiproliferative activity against HAP1MTAP–/– cells is 10 nM. MAT2A-IN-24 can be used in the research field of tumor diseases associated with MTAP deficiency .

HY-170501

MAT2A-IN-18	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-18 (Compound 15) is an inhibitor for methionine adenosyltransferase 2A (MAT2A) with an IC₅₀≤50 nM .

HY-170906S

MAT2A-IN-23	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-23 (compound 39) is a *MAT2A* inhibitor, with an IC₅₀ of 4 nM. MAT2A-IN-23 inhibits SAM in the HCT-116 (MTAP ^−/−) and in the HCT-116 WT cell line with IC₅₀s of 3 and 2 nM, respectively. MAT2A-IN-23 inhibits SDMA in the HCT-116 (MTAP ^−/−) and in the HCT-116 WT cell line with IC₅₀s of 2 and >3000 nM, respectively. MAT2A-IN-23 inhibits HCT-116 (MTAP ^−/−) cell proliferation with with an IC₅₀ of 47 nM .

HY-170502

MAT2A-IN-19	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-19 (Compound I-3) is an inhibitor for methionine adenosyltransferase 2A (MAT2A) with an IC₅₀ of 32.93 nM .

HY-183568

MAT2A-IN-26	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-26 is an orally active *MAT2A* inhibitor with a human IC₅₀ of 17.53 nM. MAT2A-IN-26 inhibits the enzymatic activity of *MAT2A, thereby reducing the levels of S-adenosylmethionine (SAM) and symmetric dimethylarginine (sDMA). MAT2A-IN-26 inhibits* the proliferation of MTAP-deficient cancer cells and induces anti-tumor efficacy in xenograft models. MAT2A-IN-26 can be used in non-small cell lung cancer research .

HY-181285

MAT2A ligand 1	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A ligand 1 is a *MAT2A* ligand inhibitor (IC₅₀₌29.5 nM) and PET tracer that crosses the blood-brain barrier. MAT2A ligand 1 enables non-invasive imaging of MAT2A-expressing tumors, with rapid tumor uptake equilibrium, a high tumor-to-muscle ratio, and specific tumor-binding properties. MAT2A ligand 1 is applicable to research related to non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, gastric cancer, glioblastoma, pancreatic adenocarcinoma, urothelial carcinoma, breast cancer, and prostate cancer .

HY-107778R

PF-9366 (Standard)	Reference Standards Methionine Adenosyltransferase (MAT)	Cancer
PF-9366 (Standard) is the analytical standard of PF-9366 (HY-107778). This product is intended for research and analytical applications. PF-9366 is a human methionine adenosyltransferase 2A (Mat2A) inhibitor, with an IC₅₀ of 420 nM and a K_d of 170 nM.

HY-182400

AGI-25696	Methionine Adenosyltransferase (MAT)	Cancer
AGI-25696 is an orally active ethionine adenosyltransferase 2A (MAT2A) inhibitor with an IC₅₀ of 97 nM. AGI-25696 reduces intracellular SAM levels in cancer cells. AGI-25696 inhibits tumor growth in mice bearing subcutaneous KP4 MTAP-null pancreatic xenografts. AGI-25696 can be used for the research of mtap-deleted pancreatic cancer .

HY-179622

ZS34	Methionine Adenosyltransferase (MAT)	Cancer
ZS34 is a potent, orally active, and selective *MAT2A* inhibitor with an IC₅₀ of 13.7 nM, displaying minimal hERG and UGT1A1 liabilities. ZS34 selectively suppresses the growth of methylthioadenosine phosphorylase (MTAP)-deficient cancer cells by inhibiting SAM synthesis, reducing SDMA levels, and inducing DNA damage. ZS34 exhibits antitumor efficacy in a HCT116 MTAP ^-/- xenograft mouse model. ZS34 can be used for the research of MTAP-deficient cancer .

Cat. No.	Product Name	Chemical Structure

HY-170905S

MAT2A-IN-22
MAT2A-IN-22 (Compound 29-1) is a BBB-penetrable and orally active *MAT2A* inhibitor with an IC₅₀ of 4 nM. MAT2A-IN-22 shows selectivity and inhibitory activity against MTAP-deficient cancer cell lines. MAT2A-IN-22 has anti-tumor effects .

HY-170906S

MAT2A-IN-23
MAT2A-IN-23 (compound 39) is a *MAT2A* inhibitor, with an IC₅₀ of 4 nM. MAT2A-IN-23 inhibits SAM in the HCT-116 (MTAP ^−/−) and in the HCT-116 WT cell line with IC₅₀s of 3 and 2 nM, respectively. MAT2A-IN-23 inhibits SDMA in the HCT-116 (MTAP ^−/−) and in the HCT-116 WT cell line with IC₅₀s of 2 and >3000 nM, respectively. MAT2A-IN-23 inhibits HCT-116 (MTAP ^−/−) cell proliferation with with an IC₅₀ of 47 nM .

MAT2A-IN-23

MAT2A-IN-23 (compound 39) is a MAT2A inhibitor, with an IC₅₀ of 4 nM. MAT2A-IN-23 inhibits SAM in the HCT-116 (MTAP ^−/−) and in the HCT-116 WT cell line with IC₅₀s of 3 and 2 nM, respectively. MAT2A-IN-23 inhibits SDMA in the HCT-116 (MTAP ^−/−) and in the HCT-116 WT cell line with IC₅₀s of 2 and >3000 nM, respectively. MAT2A-IN-23 inhibits HCT-116 (MTAP ^−/−) cell proliferation with with an IC₅₀ of 47 nM .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: